Novothirteen (Catridecacog)

Catridecacog, the active ingredient in Novothirteen, is a recombinant factor VIIIa activator presented as a sterile lyophilised powder for intravenous use. It is designed to replace the missing activated factor VIII activity in patients with hemophilia A who have developed inhibitors, helping to control and prevent bleeding episodes.

GNH USA supplies Novothirteen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product meets EU regulatory standards and is distributed under strict quality controls.

Novothirteen is used within the hemophilia A therapeutic pathway to manage bleeding in patients with factor VIII inhibitors. - Hemophilia A with inhibitors: prophylaxis of spontaneous and traumatic bleeding episodes - Hemophilia A with inhibitors: treatment of acute bleeding events - Hemophilia A with inhibitors undergoing surgery: control of peri‑operative bleeding

Novothirteen may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain or erythema - Headache - Fever - Nausea

Serious or Rare Side Effects: - Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism) - Anaphylactic or severe hypersensitivity reactions - Development of neutralising antibodies - Disseminated intravascular coagulation

When using Novothirteen, several precautions should be observed to ensure patient safety and product integrity. - Verify inhibitor status: confirm presence of factor VIII inhibitors before initiating therapy - Monitor for thrombotic complications: assess for signs of clot formation during and after treatment - Assess hypersensitivity history: avoid use in patients with known allergy to catridecacog or its excipients - Use cautiously in cardiovascular disease: evaluate risk of thrombosis in patients with coronary artery disease - Pregnancy and lactation: limited data; prescribe only if potential benefit justifies potential risk - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake

Novothirteen can interact with other medicines, affecting clotting balance.

Major Interactions (Avoid): - Concurrent use of other activated clotting factor products (e.g., recombinant factor VIIa) – increased risk of thrombosis - High‑dose estrogen‑containing therapies – heightened thrombotic potential

Moderate Interactions (Monitor Closely): - Antifibrinolytic agents (tranexamic acid, aminocaproic acid) – may augment clot formation, monitor closely - Heparin or low‑molecular‑weight heparin – possible reduction in anticoagulant effect, adjust dosing as needed - Antiplatelet drugs (aspirin, clopidogrel) – may increase bleeding risk, observe patient response